TXMD - TherapeuticsMD, Inc.
NASDAQ
->
Healthcare
->
Drug Manufacturers—Specialty & Generic
Boca Raton,
United States
Type: Equity
TXMD price evolution
TXMD
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $5.05 | $5.23 | $4.34 | $4.33 |
| Short term investments | ||||
| Net receivables | $3.32 | $2.91 | $3.22 | $3.09 |
| Inventory | ||||
| Total current assets | $12.15 | $11.82 | $11.52 | $11.8 |
| Long term investments | ||||
| Property, plant & equipment | $6.3 | $6.5 | $6.69 | $6.87 |
| Goodwill & intangible assets | $4.52 | $5.96 | $6.1 | |
| Total noncurrent assets | $28.3 | $30.57 | $31.51 | |
| Total investments | ||||
| Total assets | $39.55 | $40.13 | $42.09 | $43.31 |
| Current liabilities | ||||
| Accounts payable | $0.23 | $0.14 | $0.14 | $0.03 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $5.98 | $5.82 | $6.47 | $6.85 |
| Long term debt | $6 | $6.32 | $6.53 | |
| Total noncurrent liabilities | $6.64 | $6.96 | $7.17 | |
| Total debt | $6 | $6.32 | $6.53 | |
| Total liabilities | $12.46 | $12.46 | $13.42 | $14.02 |
| Shareholders' equity | ||||
| Retained earnings | -$952.07 | -$951.47 | -$950.38 | -$949.64 |
| Other shareholder equity | ||||
| Total shareholder equity | $27.67 | $28.66 | $29.29 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.33 | $38.07 | $65.12 | $80.49 |
| Short term investments | ||||
| Net receivables | $3.09 | $36.18 | $32 | |
| Inventory | $7.62 | $5 | ||
| Total current assets | $11.8 | $55.35 | $119.47 | $128 |
| Long term investments | ||||
| Property, plant & equipment | $6.87 | $7.66 | $9.43 | $12 |
| Goodwill & intangible assets | $6.1 | $6.94 | $40.32 | $41.44 |
| Total noncurrent assets | $31.51 | $35.11 | $50 | $53.21 |
| Total investments | ||||
| Total assets | $43.31 | $90.46 | $169.47 | $182 |
| Current liabilities | ||||
| Accounts payable | $0.03 | $2.16 | $20.32 | $23 |
| Deferred revenue | ||||
| Short long term debt | $188.27 | $2 | ||
| Total current liabilities | $6.85 | $46.84 | $252.89 | $59 |
| Long term debt | $6.53 | $7.37 | $8.06 | $246 |
| Total noncurrent liabilities | $7.17 | $8.48 | $10.2 | $246.37 |
| Total debt | $6.53 | $7.37 | $196.33 | $248.63 |
| Total liabilities | $14.02 | $55.31 | $263.09 | $306 |
| Shareholders' equity | ||||
| Retained earnings | -$949.64 | -$939.36 | -$1051.36 | -$879 |
| Other shareholder equity | ||||
| Total shareholder equity | $29.29 | $35.14 | -$93.62 | -$124 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.55 | $0.23 | $0.31 | $0.5 |
| Cost of revenue | ||||
| Gross Profit | $0.23 | $0.31 | $0.5 | |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | $1.23 | $1.32 | $1.48 | |
| Total operating expenses | $1.41 | $2.67 | $1.46 | $2.11 |
| Operating income | -$2.44 | -$1.14 | -$1.61 | |
| Income from continuing operations | ||||
| EBIT | -$1.08 | -$0.73 | -$1.04 | |
| Income tax expense | -$0.04 | |||
| Interest expense | -$0 | $0.01 | -$0.12 | |
| Net income | ||||
| Net income | -$0.61 | -$1.09 | -$0.73 | -$0.88 |
| Income (for common shares) | -$1.09 | -$0.73 | -$0.88 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $1.3 | $69.96 | $65 | |
| Cost of revenue | $1.4 | $17 | ||
| Gross Profit | $1.3 | $68.57 | $48 | |
| Operating activities | ||||
| Research & development | $10 | |||
| Selling, general & administrative | $8.9 | $57.9 | $193 | |
| Total operating expenses | $9.82 | $67.38 | $205.41 | |
| Operating income | -$8.52 | $1.19 | -$156 | |
| Income from continuing operations | ||||
| EBIT | -$10.32 | $112 | -$311 | |
| Income tax expense | -$0.04 | |||
| Interest expense | $29 | |||
| Net income | ||||
| Net income | -$10.28 | $112 | -$184 | |
| Income (for common shares) | -$10.28 | $112 | -$184 | |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$1.09 | -$0.73 | -$0.88 | |
| Operating activities | ||||
| Depreciation | $0.18 | $0.13 | $0.64 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $0.1 | $0.11 | $0.12 | |
| Total cash flows from operations | $0.67 | $0.24 | -$7.84 | |
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | ||||
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $2 | |||
| Net borrowings | ||||
| Total cash flows from financing | $2 | |||
| Effect of exchange rate | ||||
| Change in cash and equivalents | $0.72 | $0.89 | $0.01 | -$5.84 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$10.28 | $112 | -$172.41 | -$184 |
| Operating activities | ||||
| Depreciation | $0.92 | $1.19 | $4.09 | $5 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.27 | $11.57 | $18.13 | $10.68 |
| Total cash flows from operations | -$48.14 | -$4.08 | -$142.69 | -$159 |
| Investing activities | ||||
| Capital expenditures | -$0.03 | -$0.21 | ||
| Investments | ||||
| Total cash flows from investing | $223.48 | -$2.22 | -$2 | |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $3.15 | $2.47 | $184.67 | $32 |
| Net borrowings | -$221.05 | -$55.12 | $49 | |
| Total cash flows from financing | $3.15 | -$235.21 | $129.55 | $81 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$44.99 | -$15.8 | -$15.36 | -$80 |
News
|
25 Countries With Highest Abortion Rates
Insider Monkey via Yahoo Finance
12 Mar 2024
|
|
12 Best Prenatal Vitamins For Pregnant Women
Insider Monkey via Yahoo Finance
30 Jan 2024
|
|
Organogenesis (ORGO) Lags Q3 Earnings and Revenue Estimates
Zacks via Yahoo Finance
21 Mar 2023
|
|
TherapeuticsMD: Challenged Women's Health Company Needs A Savior (NASDAQ:TXMD)
Seeking Alpha
17 Nov 2022
|
|
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors
Market Watch
17 Nov 2022
|
|
TherapeuticsMD Inc. stock falls Tuesday, underperforms market
Market Watch
16 Nov 2022
|
|
TherapeuticsMD (TXMD) Reports Q3 Loss, Lags Revenue Estimates
Zacks via Yahoo Finance
15 Nov 2022
|
|
TherapeuticsMD Inc. stock falls Monday, underperforms market
Market Watch
15 Nov 2022
|
|
TherapeuticsMD Stock: Looking To Annovera To Save The Day
Seeking Alpha
17 Aug 2022
|
|
TherapeuticsMD (NYSE:TXMD) Stock Rating Upgraded by StockNews.com
ETF DAILY NEWS
17 Aug 2022
|
Fundamentals
| Market cap | $12.69M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 11.53M |
| Revenue | $1.60M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$3.32M |
| Revenue Q/Q | -1.13K% |
| Revenue Y/Y | -18.24% |
| P/E ratio | -3.83 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 7.95 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.44 |
| EPS | -$0.29 |
|---|---|
| ROA | -8.04% |
| ROE | N/A |
| Debt/Equity | 0.48 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.03 |
| Quick ratio | N/A |